Honma_2024_Biol.Pharm.Bull_47_37

Reference

Title : Vildagliptin Treatment Ameliorates Renal Interstitial Fibrosis in a Murine Model of Unilateral Ureteral Obstruction - Honma_2024_Biol.Pharm.Bull_47_37
Author(s) : Honma S , Kakuage S , Morita Y , Ito T , Yoshida M
Ref : Biol Pharm Bull , 47 :37 , 2024
Abstract :

Renal interstitial fibrosis in mice can be modeled using unilateral ureteral obstruction (UUO). Here, we investigated the anti-fibrotic effects of the dipeptidyl peptidase-4 inhibitor vildagliptin in this model. We found that vildagliptin given in the drinking water at 10.6 +/- 1.5 mg/kg/d prevented fibrosis. Mechanistically, UUO was associated with extracellular signal-regulated kinase (ERK) phosphorylation and with the accumulation of the toxic lipid peroxidation product expression of 4-hydroxy-2-nonenal (4-HNE). Both were significantly inhibited by vildagliptin. Similarly, UUO caused reductions in heme oxygenase-1 (HO-1) mRNA in the kidney, whereas interleukin-6 (IL-6) and cyclooxygenase-1 (COX-1) mRNA were increased; these effects were also prevented by vildagliptin. Taking these data together, we propose that vildagliptin reduces renal interstitial fibrosis resulting from UUO by means of its effects on ERK phosphorylation and the amounts of 4-HNE, HO-1, IL-6 and COX-1 in the kidney.

PubMedSearch : Honma_2024_Biol.Pharm.Bull_47_37
PubMedID: 38171778

Related information

Citations formats

Honma S, Kakuage S, Morita Y, Ito T, Yoshida M (2024)
Vildagliptin Treatment Ameliorates Renal Interstitial Fibrosis in a Murine Model of Unilateral Ureteral Obstruction
Biol Pharm Bull 47 :37

Honma S, Kakuage S, Morita Y, Ito T, Yoshida M (2024)
Biol Pharm Bull 47 :37